PGLYRP2

Across TCGA pan-cancer cohorts, PGLYRP2 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PGLYRP2 data layer compared with 22 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in kidney renal papillary cell carcinoma (KIRP), where higher PGLYRP2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated PGLYRP2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

KIRP, COAD, and PCPG are the cancer types where PGLYRP2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRP	DFS	Median	All	0.508	0.920	<.001	12	view →
COAD	OS	Median	III,IV	0.159	0.692	.021	12	view →
PCPG	DFS	Median	All	0.088	0.768	.002	6	view →
UCEC	OS	Median	All	0.959	0.655	.033	4	view →
SKCM	OS	Median	III,IV	0.230	0.729	<.001	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PGLYRP2–KIRP (DFS)

Open the KIRP breakdown →